JP2014519510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519510A5 JP2014519510A5 JP2014514091A JP2014514091A JP2014519510A5 JP 2014519510 A5 JP2014519510 A5 JP 2014519510A5 JP 2014514091 A JP2014514091 A JP 2014514091A JP 2014514091 A JP2014514091 A JP 2014514091A JP 2014519510 A5 JP2014519510 A5 JP 2014519510A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- residue
- polypeptide
- γglu
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 6
- 235000014304 histidine Nutrition 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 235000009697 arginine Nutrition 0.000 claims 4
- 235000009582 asparagine Nutrition 0.000 claims 4
- 229960001230 asparagine Drugs 0.000 claims 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 4
- 235000013922 glutamic acid Nutrition 0.000 claims 4
- 239000004220 glutamic acid Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 235000004554 glutamine Nutrition 0.000 claims 2
- 235000018977 lysine Nutrition 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229960003611 pramlintide Drugs 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169405 | 2011-06-10 | ||
| EP11169405.5 | 2011-06-10 | ||
| US201161496113P | 2011-06-13 | 2011-06-13 | |
| US61/496,113 | 2011-06-13 | ||
| PCT/EP2012/060899 WO2012168431A2 (en) | 2011-06-10 | 2012-06-08 | Polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519510A JP2014519510A (ja) | 2014-08-14 |
| JP2014519510A5 true JP2014519510A5 (enExample) | 2015-07-23 |
| JP6121992B2 JP6121992B2 (ja) | 2017-04-26 |
Family
ID=47295518
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514092A Active JP6247205B2 (ja) | 2011-06-10 | 2012-06-08 | ポリペプチド |
| JP2014514090A Pending JP2014519509A (ja) | 2011-06-10 | 2012-06-08 | ポリペプチド |
| JP2014514091A Active JP6121992B2 (ja) | 2011-06-10 | 2012-06-08 | ポリペプチド |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514092A Active JP6247205B2 (ja) | 2011-06-10 | 2012-06-08 | ポリペプチド |
| JP2014514090A Pending JP2014519509A (ja) | 2011-06-10 | 2012-06-08 | ポリペプチド |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8741836B2 (enExample) |
| EP (3) | EP2718315B1 (enExample) |
| JP (3) | JP6247205B2 (enExample) |
| KR (1) | KR102066987B1 (enExample) |
| CN (3) | CN103649115B (enExample) |
| AU (1) | AU2012266269B2 (enExample) |
| BR (1) | BR112013031268B1 (enExample) |
| CA (1) | CA2838884C (enExample) |
| ES (1) | ES2664509T3 (enExample) |
| IL (1) | IL229258B (enExample) |
| MX (1) | MX341324B (enExample) |
| MY (1) | MY161773A (enExample) |
| PL (1) | PL2718316T3 (enExample) |
| RS (1) | RS59977B1 (enExample) |
| RU (1) | RU2669999C2 (enExample) |
| SI (1) | SI2718316T1 (enExample) |
| WO (3) | WO2012168430A2 (enExample) |
| ZA (1) | ZA201309174B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012168430A2 (en) | 2011-06-10 | 2012-12-13 | Novo Nordisk A/S | Polypeptides |
| US8575091B1 (en) * | 2012-04-19 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
| GEP201706762B (en) | 2013-05-28 | 2017-10-25 | Takeda Pharmaceuticals Co | Peptide compound |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| TW201625671A (zh) * | 2014-09-04 | 2016-07-16 | 諾佛 儂迪克股份有限公司 | 新穎澱粉素及降鈣素受體促效劑 |
| JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| MX366174B (es) | 2014-12-23 | 2019-07-01 | Colgate Palmolive Co | Composicion de cuidado oral. |
| CN105985995A (zh) * | 2015-01-29 | 2016-10-05 | 暨南大学 | 一种利用家蚕生物反应器生产普兰林肽(pa)的方法 |
| JP6769984B2 (ja) * | 2015-03-18 | 2020-10-14 | ジーランド ファーマ アクティーゼルスカブ | アミリン類似体 |
| CN106554405B (zh) * | 2015-09-30 | 2020-04-24 | 深圳翰宇药业股份有限公司 | 一种多肽及其用途、制备方法 |
| CN106928086B (zh) * | 2015-12-31 | 2019-05-31 | 深圳翰宇药业股份有限公司 | 一种长链化合物的制备方法 |
| WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
| US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
| JP7076442B2 (ja) | 2016-11-07 | 2022-05-27 | ノヴォ ノルディスク アー／エス | Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用 |
| JP6633777B2 (ja) | 2017-08-24 | 2020-01-22 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１組成物及びその使用 |
| CN113195524A (zh) | 2018-10-11 | 2021-07-30 | 因塔西亚治疗公司 | 人类胰淀素类似物多肽和使用方法 |
| CN119455003A (zh) | 2019-02-12 | 2025-02-18 | Ambrx公司 | 包含抗体-tlr激动剂缀合物的组合物、方法和用途 |
| JP7505713B2 (ja) * | 2019-02-22 | 2024-06-25 | ロヨラ メリーマウント ユニバーシティ | アミロイドペプチドバリアント |
| EP4058047A1 (en) | 2019-11-11 | 2022-09-21 | Boehringer Ingelheim International GmbH | Npy2 receptor agonists |
| AU2021208601B2 (en) * | 2020-02-18 | 2025-06-05 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| KR20230045088A (ko) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 가용성 npy2 수용체 작용제 |
| AU2021327396A1 (en) | 2020-08-20 | 2023-03-23 | Ambrx, Inc. | Antibody-TLR agonist conjugates, methods and uses thereof |
| JP2023544959A (ja) | 2020-09-24 | 2023-10-26 | グブラ エー／エス | 改善されたアミリン受容体（ｈＡＭＹ３Ｒ）効力を有するｈＡＭ１５－５２類似体 |
| TWI850611B (zh) | 2020-12-18 | 2024-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
| TWI815327B (zh) * | 2021-03-03 | 2023-09-11 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| MX2023011480A (es) | 2021-04-03 | 2023-12-06 | Ambrx Inc | Conjugados anticuerpo anti-her2-fármaco y usos de estos. |
| WO2022248419A2 (en) | 2021-05-22 | 2022-12-01 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4144362A1 (en) | 2021-09-06 | 2023-03-08 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4129324A1 (en) | 2021-08-02 | 2023-02-08 | Adocia | Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist |
| AU2022386166A1 (en) | 2021-11-10 | 2024-06-20 | I2O Therapeutics, Inc. | Ionic liquid compositions |
| TWI876242B (zh) | 2021-12-13 | 2025-03-11 | 丹麥商諾佛 儂迪克股份有限公司 | 包括環糊精的醫藥調配物 |
| CN118973602A (zh) | 2022-03-30 | 2024-11-15 | 诺和诺德股份有限公司 | 配制方法 |
| EP4534553A1 (en) * | 2022-05-27 | 2025-04-09 | Hangzhou Sciwind Biosciences Co., Ltd. | Human amylin analog, and derivative and use thereof |
| CN119923269A (zh) | 2022-09-19 | 2025-05-02 | 西兰制药公司 | 组合治疗 |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| EP4638480A1 (en) | 2022-12-22 | 2025-10-29 | Novo Nordisk A/S | Amylin receptor agonists |
| GB2641696A (en) * | 2023-02-10 | 2025-12-10 | Hangzhou Sciwind Biosciences Co Ltd | Polypeptide and derivative thereof, composition, and use thereof |
| TW202500183A (zh) | 2023-06-15 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 包括環糊精的醫藥調配物 |
| WO2024261076A1 (en) | 2023-06-21 | 2024-12-26 | Zealand Pharma A/S | Weight loss |
| AU2024312389A1 (en) | 2023-06-21 | 2025-12-04 | Zealand Pharma A/S | Analogues with improved properties |
| WO2025003471A1 (en) | 2023-06-30 | 2025-01-02 | Zealand Pharma A/S | Combination therapy |
| WO2025114501A1 (en) | 2023-11-30 | 2025-06-05 | Novo Nordisk A/S | Tri-agonists of the glp-1, gip, and amylin receptors |
| WO2025160082A1 (en) * | 2024-01-23 | 2025-07-31 | Viking Therapeutics, Inc. | Amylin analogs |
| WO2025168049A1 (zh) * | 2024-02-07 | 2025-08-14 | 江苏恒瑞医药股份有限公司 | 胰岛淀粉样多肽类似物及其医药用途 |
| EP4603080A1 (en) | 2024-02-16 | 2025-08-20 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4603079A1 (en) | 2024-02-16 | 2025-08-20 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| WO2025172605A1 (en) | 2024-02-16 | 2025-08-21 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| WO2025172606A1 (en) | 2024-02-16 | 2025-08-21 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA936811B (en) * | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| JP4372345B2 (ja) | 1998-02-13 | 2009-11-25 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 新規な混合アミリン活性化合物 |
| WO1999057147A1 (fr) * | 1998-04-30 | 1999-11-11 | Kirin Brewery Company, Limited | Mutants de la thrombopoietine humaine |
| AU4930299A (en) * | 1998-07-31 | 2000-02-21 | Kirin Beer Kabushiki Kaisha | Remedies for neuropathy containing as the active ingredient galectin-1 or its derivatives |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1730186A2 (en) * | 2004-03-31 | 2006-12-13 | Xencor, Inc. | Bmp-7 variants with improved properties |
| CN101400698A (zh) * | 2006-03-15 | 2009-04-01 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽衍生物 |
| WO2008086086A2 (en) * | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2293811A1 (en) | 2008-06-25 | 2011-03-16 | Novo Nordisk A/S | Derivatised hybrid peptides of amylin and salmon calcitonin |
| JP5703226B2 (ja) * | 2008-10-21 | 2015-04-15 | ノヴォ ノルディスク アー／エス | アミリン誘導体 |
| JP5850848B2 (ja) | 2009-11-25 | 2016-02-03 | ノヴォ ノルディスク アー／エス | ポリペプチドの製造方法 |
| WO2012168430A2 (en) * | 2011-06-10 | 2012-12-13 | Novo Nordisk A/S | Polypeptides |
-
2012
- 2012-06-08 WO PCT/EP2012/060897 patent/WO2012168430A2/en not_active Ceased
- 2012-06-08 BR BR112013031268-8A patent/BR112013031268B1/pt active IP Right Grant
- 2012-06-08 JP JP2014514092A patent/JP6247205B2/ja active Active
- 2012-06-08 CN CN201280028642.1A patent/CN103649115B/zh active Active
- 2012-06-08 PL PL12729418T patent/PL2718316T3/pl unknown
- 2012-06-08 CN CN201280028554.1A patent/CN103596972B/zh active Active
- 2012-06-08 EP EP12729417.1A patent/EP2718315B1/en active Active
- 2012-06-08 RS RS20200191A patent/RS59977B1/sr unknown
- 2012-06-08 CA CA2838884A patent/CA2838884C/en active Active
- 2012-06-08 KR KR1020137034732A patent/KR102066987B1/ko active Active
- 2012-06-08 WO PCT/EP2012/060899 patent/WO2012168431A2/en not_active Ceased
- 2012-06-08 JP JP2014514090A patent/JP2014519509A/ja active Pending
- 2012-06-08 US US13/491,883 patent/US8741836B2/en active Active
- 2012-06-08 SI SI201231728T patent/SI2718316T1/sl unknown
- 2012-06-08 US US13/491,885 patent/US8722849B2/en active Active
- 2012-06-08 ES ES12729417.1T patent/ES2664509T3/es active Active
- 2012-06-08 AU AU2012266269A patent/AU2012266269B2/en active Active
- 2012-06-08 JP JP2014514091A patent/JP6121992B2/ja active Active
- 2012-06-08 EP EP12729416.3A patent/EP2718314A2/en not_active Withdrawn
- 2012-06-08 EP EP12729418.9A patent/EP2718316B1/en active Active
- 2012-06-08 RU RU2013156937A patent/RU2669999C2/ru active
- 2012-06-08 WO PCT/EP2012/060900 patent/WO2012168432A1/en not_active Ceased
- 2012-06-08 MX MX2013013913A patent/MX341324B/es active IP Right Grant
- 2012-06-08 CN CN201280028644.0A patent/CN103596973A/zh active Pending
- 2012-06-08 MY MYPI2013004133A patent/MY161773A/en unknown
- 2012-06-08 US US13/491,880 patent/US8575090B2/en active Active
-
2013
- 2013-09-26 US US14/038,265 patent/US9029325B2/en active Active
- 2013-11-05 IL IL22925813A patent/IL229258B/en active IP Right Grant
- 2013-12-05 ZA ZA2013/09174A patent/ZA201309174B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519510A5 (enExample) | ||
| JP2014519509A5 (enExample) | ||
| JP2014519511A5 (enExample) | ||
| RU2013156937A (ru) | Полипептиды | |
| JP2012506402A5 (enExample) | ||
| DK2651398T3 (en) | Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid | |
| RU2207874C9 (ru) | Производное инсулина или его физиологически приемлемая соль, предшественник производного инсулина, днк-последовательность, кодирующая предшественник, вектор экспрессии, содержащий упомянутую днк-последовательность, субстрат, трансформированный упомянутым вектором экспрессии, фармацевтическая композиция с понижающей, соответственно регулирующей уровень глюкозы в крови эффективностью | |
| Gault et al. | Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| RU98112109A (ru) | Производное инсулина или его физиологически приемлемая соль, предшественник производного инсулина, днк-последовательность, кодирующая предшественник, вектор экспрессии, содержащий упомянутую днк-последовательность, субстрат, трансформированный упомянутым вектором экспрессии, и фармацевтическая композиция с понижающей, соответственно регулирующей уровень глюкозы в крови эффективностью | |
| AR070119A1 (es) | Derivados de insulina con perfil tiempo / accion extremadamente retardado | |
| JP2014529629A5 (enExample) | ||
| JP2008533105A5 (enExample) | ||
| JP2005528337A5 (enExample) | ||
| JP2010538049A5 (enExample) | ||
| JP2016188225A (ja) | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド | |
| JP2015517459A5 (enExample) | ||
| RU2010133233A (ru) | Новые производные инсулина с сильно замедленным профилем время/действие | |
| JP2014501712A5 (enExample) | ||
| JP2013545724A (ja) | 作用持続時間が増した改変ポリペプチド | |
| TW202233227A (zh) | 腸促胰島素(incretin)類似物及其用途 | |
| JP2012529463A (ja) | ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ | |
| WO2013148966A1 (en) | Transmucosal delivery of engineered polypeptides | |
| JP2016500682A5 (enExample) | ||
| JP2011526886A5 (enExample) |